Notice NOT-DK-22-026 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-028 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

Notice NOT-CA-22-121 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-030 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT network, facilitate data sharing and collaboration, and coordinate clinical trial activities between research sites and the NCI.

Funding Opportunity RFA-CA-22-029 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

Funding Opportunity RFA-NS-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This FOA is not specific for any one or group within the AD/ADRD spectrum of disorders. Disorders, and includes genome editing therapies for: Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), Alzheimers Disease (AD) and Multiples Etiology Dementias (MED).

Funding Opportunity RFA-DK-22-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to invite applicationsfor for clinical centers for the continuation of the Drug-Induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA- DK-22-508) seeks to continue the Data Coordinating Center for DILIN. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, dietary and herbal supplements have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN throughout its publications has become the major source of information and progress in understanding the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.

Funding Opportunity RFA-DK-22-508 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and build a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in Herbal and Dietary Supplements (HDS) implicated in liver toxicity. This RFA and companion [RFA-DK-22-013, Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)] will seek the continuation of the Data Coordinating Center and several Clinical Centers. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN through its publications has become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.

Funding Opportunity RFA-DK-22-507 from the NIH Guide for Grants and Contracts. This FOA invites a cooperative agreement application to renew the APOL1 Long-term Kidney Transplantation Outcomes Research Network (APOLLO) Scientific Data Research Center (SDRC), with a continued charge to coordinate the clinical and research efforts of the APOLLO Consortium. This FOA runs in parallel with a separate FOA that invites applications for the APOLLO Clinical Centers (CCs) (RFA-DK-221-506). The APOLLO Network study results are expected to enhance understanding of associations of APOL1 genotype with renal transplant outcomes and provide evidence for optimizing allocation and management approaches to kidney donation in individuals of African ancestry.

Notice NOT-AT-22-032 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-122 from the NIH Guide for Grants and Contracts

Notice NOT-OH-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-OH-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-OH-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-072 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-067 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-EB-22-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototypes intended for use as safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.

Funding Opportunity RFA-OH-23-001 from the NIH Guide for Grants and Contracts. NIOSH supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 Health and Compensation Act of 2010 (Public Law 111347, as amended by Public Laws 114113 and 11659).

Funding Opportunity RFA-DK-22-506 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to renew the APOL1 Long-term Kidney Transplantation Outcomes Research Network (APOLLO) Clinical Centers (CCs), with a continued charge to determine laboratory parameters and clinical events in the kidney transplant recipients, according to the clinical and research efforts of the APOLLO Consortium. This FOA runs in parallel with a separate FOA that invites applications for the APOLLO SDRC (SDRC) (RFA-DK-22-507). The APOLLO Network study results are expected to enhance understanding of the associations of APOL1 genotype with renal transplant outcomes and provide evidence for optimizing allocation and management approaches to kidney donation in individuals of African Ancestry.

Notice NOT-DA-23-005 from the NIH Guide for Grants and Contracts